Journal
COR ET VASA
Volume 56, Issue 3, Pages E235-E239Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.crvasa.2014.04.004
Keywords
Resistant hypertension; Catheter-based renal denervation; Ambulatory blood pressure; monitoring; Spironolactone; Adherence to treatment
Categories
Funding
- PRVOUK P35 Research Program of the Charles University
Ask authors/readers for more resources
Catheter-based renal denervation (RDN) was considered as a promising method for treatment of resistant hypertension and was increasingly being used worldwide. However, there are equivocal results from only two randomized trials studying the effect of such intervention. Thus, additional data from properly designed long-term comparative trials are needed. The PRAGUE-15 trial is designed as an open, prospective, randomized multicenter trial comparing RDN versus intensified medical treatment in patients with resistant hypertension. Patients randomized to the medical treatment group will receive spironolactone in the absence of contraindications. The primary endpoint will be changes in systolic and diastolic pressure during ambulatory blood pressure monitoring (ABPM) from baseline to 6 months. Herein, we describe the trial design and methodology. The strengths of the trial include ABPM (as the objective endpoint), independent outcomes assessment, and therapeutic use of spironolactone. (C) 2014 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.zo.o. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available